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A B S T R A C T   
Background: Limited large-scale studies have been conducted to investigate the adverse effects of COVID-19 
vaccine in Latin America, particularly among the healthcare worker (HCW) population in Ecuador. The objec-
tive of this study was to assess a cohort of Ecuadorian healthcare workers for adverse reactions following 
vaccination with the Pfizer-BioNTech vaccine. 
Methods: We conducted an observational cross-sectional study to assess the potential adverse reactions to the 
Pfizer-BioNTech COVID-19 vaccine among a sample of healthcare workers (HCWs) in the city of Guayaquil, 
Ecuador, from March to May 2021. 
Results: The sample comprised 1291 patients, with a mean age of 39.3 years (SD, 13.5). In general, 79% (N =
1020) of participants presented an adverse effect of any type at first dose, while 75.1% (N = 969) did so at the 
second dose. Pain at the puncture site was the most common adverse effect overall after either the first (68.4%) 
and second (55.6%) dose. Regarding anaphylaxis, no participant developed the condition after the first dose, and 
only 0.2% (N = 2) developing it at the second dose. No fatalities were reported. 
Conclusion: Our findings suggest that adverse reactions following COVID-19 vaccination with the Pfizer- 
BioNTech vaccine are relatively common, albeit often mild and self-limited. Consistent with the literature 
there were few cases of anaphylaxis, and no deaths that could be attributed to the inoculation with the vaccine. 
We hope our findings can help to reassure the public that benefits of vaccination highly outweigh the risks and 
contribute to the effort of reducing vaccine hesitancy among those who are concerned about the safety and 
potential side effects.   
1. Introduction 
The COVID-19 pandemic bears a burden on medical care and econ-
omies worldwide, however immunization at the population level pro-
vides a way for to reduce future morbidity and mortality [1]. Vaccine 
hesitancy and reluctance in getting the COVID-19 vaccine and appre-
hensions about them have been present along the course of vaccination 
programs and mass immunizations across the world [2]. Factors such as 
the quick, large-scale production of vaccines, lack of information, and 
uncertainty about adverse reactions in the public’s eye as well about 
myths spreading through media channels have given rise to suspicion 
and fear in the Latin American population [2]. Limited large-scale 
studies have been conducted to investigate the adverse effects of 
COVID-19 vaccine in Latin America, particularly among the healthcare 
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worker (HCW) population in Ecuador. The objective of this study was to 
assess a cohort of Ecuadorian healthcare workers for adverse reactions 
following vaccination with the Pfizer-BioNTech vaccine. 
2. Methods 
We conducted an observational cross-sectional study to assess the 
potential adverse reactions to the Pfizer-BioNTech COVID-19 vaccine 
among a sample of healthcare workers (HCWs) in the city of Guayaquil, 
Ecuador, from March to May 2021. All individuals involved were part of 
the first phase of the national COVID-19 vaccination plan in our country 
and were contacted through a local registry established by a local pri-
vate university. In the first telephone call, potential participants were 
explained about the purpose of the study, and only after voluntary 
informed consent was obtained further information was collected. 
Thereafter, weekly telephone calls were set up to ascertain if adverse 
reactions had occurred within 14 days of receiving the vaccine. 
This study was conducted according to the principles established by 
the Declaration of Helsinki and was approved by the Expedited Ethics 
Committee of the Ecuadorian Health Ministry (Approval N◦ 024–2020). 
With the information recollected in the survey, personal identification 
was not possible; as such, anonymity, and personal data protection was 
guaranteed. 
3. Results 
The sample comprised 1291 patients with a gender distribution of 
50.4% female and 41.6% male patients. The mean age of the sample was 
39.3 years (SD, 13.5) years (Tables 1 and 2). Around a quarter of the 
sample had at least one comorbidity (23.3%) and a past medical history 
compatible with allergic disease (23.1%), where arterial hypertension 
(11.5%) and drug allergy (10.1%) were reported as the most common 
conditions, respectively. Furthermore, 28.1% of the studied sample 
confirmed to be infected with COVID-19 in the past, at least once, no 
more than a month prior to vaccination. Regarding the vaccine regimen, 
73.1% had completed a double dose standard, while 26.9% had only 
received one dose. The average time between the first and the second 
dose was 21.5 days (SD, 1.47). 
In general, 79% (N = 1020) of participants presented an adverse 
effect of any type at first dose, while 75.1% (N = 969) did so at the 
second dose (Table 3). Local adverse effects were more common than 
systemic adverse effects at first (69.4% and 43.1%, respectively) and 
second (58.3% and 51.6%, respectively) doses. Pain at the puncture site 
was the most common adverse effect overall after either the first 
Table 1 
Demographic and clinical information of surveyed population (n =
1291).  
Characteristics Value % (N) 
Gender 
Male 41.6 (537) 
Female 58.4 (754) 
Comorbidity 23.3 (301) 
Arterial hypertension 11.5 (149) 
Diabetes 3.6 (47) 
Hypothyroidism 2.2 (29) 
Other 6.1 (79) 
History of allergic condition 23.1 (298) 
Drug allergy 10.1 (131) 
Allergic rhinitis 8.8 (113) 
Food allergy 5.1 (66) 
Asthma 3.6 (47) 
Atopic dermatitis 1.5 (19) 
Past COVID-19 infection 28.1 (363) 
Vaccine doses received 
Single dose 26.9 (347) 
Double dose 73.1 (944) 
Outpatient self-medicated 4.4 (57) 
FG-Anti-H1 4.3 (55) 
Acetaminophen 0.1 (1) 
Antibiotics 0.1 (1) 
Medical attention 1.5 (19) 
FG-Anti-H1 0.5 (7) 
Acetaminophen 34.2 (442) 
Other NSAIDs 3.5 (45) 
Notes: FG-Anti-H1, First generation antihistamine H1 receptor; 
NSAIDs, Nonsteroidal anti-inflammatory drugs. 
Table 2 
Mean age and time between outcomes of interest.  
Adverse effect Mean (SD) 
Age 39.3 (13.5) 
Days between vaccine doses 21.5 (1.47) 
Time to present adverse effect after first dosea 6.6 (6.5) 
Time for local adverse effecta 7.2 (6.6) 
Time for systemic adverse effecta 6.9 (6.5) 
Time to present adverse effect after second dosea 6.1 (5.4) 
Time for local adverse effecta 6.5 (5.5) 
Time for systemic adverse effecta 7.2 (6.2) 
Days presenting adverse effect after onset (first dose) 2.6 (1.7) 
Days for local adverse effect 2.4 (1.6) 
Days for systemic adverse effect 2.1 (1.5) 
Days presenting adverse effect after onset (second dose) 2.4 (1.7) 
Days for local adverse effect 2.3 (1.5) 
Days for systemic adverse effect 0.5 (0.4) 
Notes: 
a Time is in hours. 
Table 3 
Adverse effects frequencies at first and second doses.  
Characteristics First dose Value % (N) Second dose Value % (N) 
Adverse effect 79.0 (1020) 75.1 (969) 
Local adverse effect 69.4 (896) 58.3 (753) 
Pain 68.4 (883) 55.6 (718) 
Erythema 5.5 (71) 10.8 (139) 
Edema 8.0 (103) 12.8 (165) 
Pruritus 0.6 (8) 1.2 (16) 
Axillary edema 1.6 (21) 1.1 (14) 
Systemic adverse effect 43.1 (557) 51.6 (666) 
Fever 11.5 (149) 18.0 (233) 
Cephalea 18.1 (234) 23.8 (307) 
Malaise 19.8 (255) 28.0 (362) 
Myalgia 4.6 (60) 6.3 (81) 
Arthralgia 4.4 (5) 8.4 (109) 
Nausea/Vomiting 2.7 (35) 2.9 (38) 
Diarrhea 2.9 (37) 2.3 (30) 
Chills 3.5 (45) 6.3 (81) 
Fatigue 6.0 (78) 5.4 (70) 
Somnolence 2.6 (34) 2.3 (30) 
Syncope 0.1 (1) 0.0 (0) 
Paresthesia 1.0 (13) 1.2 (15) 
Anxiety 0.4 (5) 0.7 (9) 
Dizziness 2.7 (35) 2.2 (29) 
Epigastric pain 1.3 (17) 0.5 (7) 
Generalized rash 0.8 (10) 0.3 (4) 
Generalized pruritus 0.6 (8) 06 (8) 
Allergic rhinitis 0.2 (3) 0.5 (7) 
Petechiae 0.2 (3) 0.3 (4) 
Throat itchiness 0.6 (8) 0.2 (2) 
Allergic sinusitis 0.4 (5) 0.1 (1) 
Facial edema 0.1 (1) 0.0 (0) 
Bronchospasm 0.1 (1) 0.0 (0) 
Allergic conjunctivitis 0.1 (1) 0.1 (1) 
Dermatitis 0.0 (0) 0.1 (1) 
Ezcema 0.1 (1) 0.2 (2) 
Ocular edema 0.0 (0) 0.1 (1) 
Idiopathic urticaria 0.1 (1) 0.0 (0) 
Lip swelling 0.1 (1) 0.2 (2) 
Tongue swelling 0.1 (1) 0.0 (0) 
Lip itchiness 0.0 (0) 0.1 (1) 
Facial rash 0.1 (1) 0.0 (0) 
Anaphylaxis 0.0 (0) 0.2 (2)  
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(68.4%) and second (55.6%) dose. In sequence, malaise was the second 
most common adverse effect overall. Other local adverse effects that 
were relatively frequent were edema and erythema, whereas headache 
and fever were notable systemic adverse effects observed after either 
vaccine dose administration. Regarding anaphylaxis, no participant 
developed the condition after the first dose, and only 0.2% (N = 2) 
developing it at the second dose. No fatalities were reported. 
Overall, 79% of the HCWs had an adverse event on the first dose, 
whereas 75.1% did with the second dose. The local adverse events were 
more common with the first dose (69.4%) whereas systemic adverse 
effects were more common with the second dose. As with the CDC 
report, pain was the most common overall adverse effect. Anaphylaxis 
was observed in only 2 HCWs post the second dose with no deaths 
reported. 
4. Discussion 
The centers for disease control and prevention (CDC) finds that 
among an intervention (N = 2291) and placebo group (N = 2298), 
84.7% vaccine recipients reported at least one local injection site reac-
tion [3]. The most frequent local reaction was pain at the injection site. 
As compared to pain, swelling and redness following either dose of the 
Pfizer-BioNTech vaccine were less frequently reported [3]. Consistent 
with previous reports, we found that local adverse reactions were more 
common than systemic adverse reactions, with pain at the puncture site 
the most commonly reported event at both doses. It is worth noting that 
most of the observed reactions were mild or moderate in severity, which 
coincides with the reports on vaccine safety [1]. 
On the other hand, serious adverse events are defined as any unto-
ward medical occurrence that results in death, is life threatening, and 
that requires hospitalization, possibly leading to persistent disability. 
The percentage of serious adverse events in the vaccine (0.6%) and 
placebo group (0.5%) have been somewhat similar, with two events 
namely shoulder injury and lymphadenopathy documented by the FDA 
post vaccination [3]. Overall, the FDA and CDC reports state that the risk 
of serious adverse events that involve organ classes are balanced be-
tween placebo and vaccine groups. Our study results are consistent with 
reported literature, as we found no cases of serious adverse events 
related to the vaccination with either dose. 
When immunizing the general population with the Pfizer BioNTech 
vaccine, anaphylaxis, which is a severe, rapid-onset, multisystem 
allergic reaction, was reported in 11.1 cases per 1 million infections [4]. 
This trend was estimated to be up to ten-fold higher than previous, 
commonly used vaccines. When more estimates were generated, and 
millions of doses of the COVID-19 vaccines were administered, the 
updated anaphylaxis rate was determined to be 4.7 cases per 1 million 
doses. Notably, 90% of the anaphylactic reactions were reported among 
females, and 81% of the individuals had a history of allergies [4]. 
Consistent with previous findings, no participants in our study reported 
an anaphylactic event at the first dose, and only 0.2% developed it at the 
second dose. Coincidentally, the two patients that developed anaphy-
laxis were females. In this regard, further studies are needed to accu-
rately assess the allergenic components responsible for anaphylaxis so 
high-risk patients can be identified and counseled properly to prevent 
this type of event. 
There are increasing concerns among physicians and patients about 
adverse reactions to the COVID-19 vaccines [5]. Given that the vaccine 
production is concentrated in the Global North, governments in the 
Global South do not have their preference in picking vaccines for the 
citizens [6]. Vaccine hesitancy in Latin America is non-uniform, largely 
dependent on which vaccine is offered. Data from Latin America sug-
gests that citizens may have imprecise beliefs about public health issues, 
and the misinformation can lead to hesitancy in acquiring the vaccine 
[6]. With few studies conducted in Latin America in this area, we hope 
our findings can help to reassure the public that benefits of vaccination 
highly outweigh the risks and contribute to the effort of reducing 
vaccine hesitancy among those who are concerned about the safety and 
potential side effects. 
In light of our findings, there are several limitations worth 
mentioning. Our sample consisted of healthcare workers who had been 
informed about the study’s purpose before participating, which may 
have affected their perception of adverse effects. Also, participants were 
asked to identify past adverse events, so recall bias might have been 
present. However, to our knowledge this study is among the first to 
report the occurrence of adverse reactions related to COVID-19 in an 
Ecuadorian population. 
5. Conclusions 
Our findings suggest that adverse reactions following COVID-19 
vaccination with the Pfizer-BioNTech vaccine are relatively common, 
albeit often mild and self-limited. Local reactions such as pain in the 
injection site account for the majority of events, while systemic/severe 
reactions are rare. Consistent with the literature there were few cases of 
anaphylaxis, and no deaths that could be attributed to the inoculation 
with the vaccine. We hope our findings can help to reassure the public 
that benefits of vaccination highly outweigh the risks and contribute to 
the effort of reducing vaccine hesitancy among those who are concerned 
about the safety and potential side effects. 
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